These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1009 related items for PubMed ID: 19695857

  • 1. Lipids, atherosclerosis and CVD risk: is CRP an innocent bystander?
    Nordestgaard BG, Zacho J.
    Nutr Metab Cardiovasc Dis; 2009 Oct; 19(8):521-4. PubMed ID: 19695857
    [Abstract] [Full Text] [Related]

  • 2. Justification for the Use of Statins in Primary Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER)--can C-reactive protein be used to target statin therapy in primary prevention?
    Mora S, Ridker PM.
    Am J Cardiol; 2006 Jan 16; 97(2A):33A-41A. PubMed ID: 16442935
    [Abstract] [Full Text] [Related]

  • 3. C-reactive protein is not only an inflammatory marker but also a direct cause of cardiovascular diseases.
    Li JJ, Fang CH.
    Med Hypotheses; 2004 Jan 16; 62(4):499-506. PubMed ID: 15050096
    [Abstract] [Full Text] [Related]

  • 4. Does elevated C-reactive protein cause human atherothrombosis? Novel insights from genetics, intervention trials, and elsewhere.
    Nordestgaard BG.
    Curr Opin Lipidol; 2009 Oct 16; 20(5):393-401. PubMed ID: 19667982
    [Abstract] [Full Text] [Related]

  • 5. The Jupiter study, CRP screening, and aggressive statin therapy-implications for the primary prevention of cardiovascular disease.
    Kones R.
    Ther Adv Cardiovasc Dis; 2009 Aug 16; 3(4):309-15. PubMed ID: 19460829
    [Abstract] [Full Text] [Related]

  • 6. Cardiovascular disease: C-reactive protein and the inflammatory disease paradigm: HMG-CoA reductase inhibitors, alpha-tocopherol, red yeast rice, and olive oil polyphenols. A review of the literature.
    Patrick L, Uzick M.
    Altern Med Rev; 2001 Jun 16; 6(3):248-71. PubMed ID: 11410071
    [Abstract] [Full Text] [Related]

  • 7. C-reactive protein, insulin resistance and risk of cardiovascular disease: a population-based study.
    Jeppesen J, Hansen TW, Olsen MH, Rasmussen S, Ibsen H, Torp-Pedersen C, Hildebrandt PR, Madsbad S.
    Eur J Cardiovasc Prev Rehabil; 2008 Oct 16; 15(5):594-8. PubMed ID: 18753952
    [Abstract] [Full Text] [Related]

  • 8. C-reactive protein and risk of venous thromboembolism in the general population.
    Zacho J, Tybjaerg-Hansen A, Nordestgaard BG.
    Arterioscler Thromb Vasc Biol; 2010 Aug 16; 30(8):1672-8. PubMed ID: 20466978
    [Abstract] [Full Text] [Related]

  • 9. [Inflammation and C-reactive protein in cardiovascular disease].
    Munk PS, Larsen AI.
    Tidsskr Nor Laegeforen; 2009 Jun 11; 129(12):1221-4. PubMed ID: 19521445
    [Abstract] [Full Text] [Related]

  • 10. Effect of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors on high-sensitivity C-reactive protein levels.
    Field KM.
    Pharmacotherapy; 2005 Oct 11; 25(10):1365-77. PubMed ID: 16185181
    [Abstract] [Full Text] [Related]

  • 11. C-reactive protein and risk of cardiovascular disease in men and women from the Framingham Heart Study.
    Wilson PW, Nam BH, Pencina M, D'Agostino RB, Benjamin EJ, O'Donnell CJ.
    Arch Intern Med; 2005 Nov 28; 165(21):2473-8. PubMed ID: 16314543
    [Abstract] [Full Text] [Related]

  • 12. From here to JUPITER: identifying new patients for statin therapy using data from the 1999-2004 National Health and Nutrition Examination Survey.
    Spatz ES, Canavan ME, Desai MM.
    Circ Cardiovasc Qual Outcomes; 2009 Jan 28; 2(1):41-8. PubMed ID: 20031811
    [Abstract] [Full Text] [Related]

  • 13. C-reactive protein, anti-C-reactive protein antibodies and clinical atherosclerosis.
    Rosenau BJ, Costenbader KH, Schur PH.
    Vasc Med; 2008 Feb 28; 13(1):25-8. PubMed ID: 18372435
    [Abstract] [Full Text] [Related]

  • 14. A triumvirate of targets in the prevention and treatment paradigm for cardiovascular disease.
    Packard C.
    Atheroscler Suppl; 2006 Apr 28; 7(1):21-9. PubMed ID: 16504600
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Predicting benefit from statins by C-reactive protein, LDL-cholesterol or absolute cardiovascular risk.
    Stewart RA.
    Future Cardiol; 2009 May 28; 5(3):231-6. PubMed ID: 19656039
    [Abstract] [Full Text] [Related]

  • 17. Inflammation and atherosclerosis: role of C-reactive protein in risk assessment.
    Libby P, Ridker PM.
    Am J Med; 2004 Mar 22; 116 Suppl 6A():9S-16S. PubMed ID: 15050187
    [Abstract] [Full Text] [Related]

  • 18. Relationships between leptin and C-reactive protein with cardiovascular disease in the adult general population.
    Romero-Corral A, Sierra-Johnson J, Lopez-Jimenez F, Thomas RJ, Singh P, Hoffmann M, Okcay A, Korinek J, Wolk R, Somers VK.
    Nat Clin Pract Cardiovasc Med; 2008 Jul 22; 5(7):418-25. PubMed ID: 18431365
    [Abstract] [Full Text] [Related]

  • 19. Rosuvastatin in hemodialysis: short-term effects on lipids and C-reactive protein.
    Burmeister JE, Miltersteiner DR, Campos BM.
    J Nephrol; 2009 Jul 22; 22(1):83-9. PubMed ID: 19229822
    [Abstract] [Full Text] [Related]

  • 20. Prognostic utility of apoB/AI, total cholesterol/HDL, non-HDL cholesterol, or hs-CRP as predictors of clinical risk in patients receiving statin therapy after acute coronary syndromes: results from PROVE IT-TIMI 22.
    Ray KK, Cannon CP, Cairns R, Morrow DA, Ridker PM, Braunwald E.
    Arterioscler Thromb Vasc Biol; 2009 Mar 22; 29(3):424-30. PubMed ID: 19122170
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 51.